CURRICULUM VITAE FOR LARS BERGLUND

 

1.         Date of preparation:  Janurary 24, 2008

 

 

2.                  Personal data.

 

Name:              Lars Berglund, M.D., Ph.D.

Date of Birth:    July 24, 1950

Place of Birth:   Borlänge, Kopparbergs län, Sweden

Citizenship:       Swedish           (Visa status:      Resident alien)

 

3.         Academic education:

 

1969-1971       Medical School, University of Uppsala, Sweden

1971                Degree: Candidate of Medicine

1971-1973       Medical School, University of Uppsala, Sweden

1973-1977       Ph.D.-student, Department of Medical and Physiological Chemistry,

                        University of Uppsala, Sweden

1977                Academic Degree: Ph.D., University of Uppsala

1977-1979             Postdoctoral fellowship, UCSD (see below)

1979-1981       Medical School, University of Uppsala, Sweden

1981                Professional Degree: M.D., University of Uppsala

 

Ph.D. - thesis:

Studies on pyruvate kinases

Sponsor: Professor Lorentz Engström, Department of Medical and Physiological Chemistry,

               University of Uppsala, Sweden

Publication: Studies on Pyruvate kinases, Acta Universitatis Upsaliensis 279, a summary containing the following five original, peer-reviewed publications (publications # 4, and 6-9 in publication list):

            Berglund L, Ljungström O, Engström L.  Purification and characterization of pig kidney pyruvate kinase (type A). Journal of Biological Chemistry (1977), 252: 6108-6111.

            Berglund L, Ljungström O, Engström L. Studies on the cyclic 3',5'-AMP-stimulated pig liver protein kinase reaction with pyruvate kinase as substrate.  Journal of Biological Chemistry (1977), 252: 613-619.

            Berglund L.  Phosphorylation of rat kidney pyruvate kinase type L by cyclic 3',5'-AMP-dependent protein kinase.  Biochimica et Biophysica Acta (1978), 524: 68-77.

            Berglund, L Humble, E.  Kinetic properties of pig pyruvate kinases type A from kidney and type M from muscle.  Archives of Biochemistry and Biophysics (1979), 195: 347-361.

            Zetterqvist Ö, Ragnarsson U, Humble E, Berglund L, Engström L. The minimum substrate of cyclic AMP-stimulated protein kinase as studied by synthetic peptides representing the phosphorylation site of pyruvate kinase (type L) of rat liver.  Biochemical and Biophysical Research Communications (1976), 70: 696-703.

 

Medical licensure:

1982        Medical Licensure, Sweden (# 500724-7116)

1997        Medical Licensure, New York State (License # 206404)

2002    Medical Licensure, California (License # A89561)

 

 

4.         Traineeship:

 

1977-1979       Postdoctoral fellow at Division of Metabolic Disease, Department of Medicine, University of California San Diego, La Jolla, California, USA

University of California San Diego (Fellow of the American Diabetes Association)

1981-1982       Rotating internship (Surgery, Anesthesiology, Internal Medicine, Psychiatry, General practice), Huddinge University Hospital , Stockholm, Sweden

1982-1984             Resident, Department of Medicine, Karolinska Institute, Huddinge University

                        Hospital, Stockholm, Sweden

1984-1986             Resident, Department of Clinical Chemistry, Karolinska Institute, Huddinge

                        University Hospital, Stockholm, Sweden

 

5.         Board qualification:

 

1986                Specialist in Clinical Chemistry (Awarded by the National Swedish Board of Health and Welfare)

1994-1996             Passed USMLE exams 1-3

1997                    Medical Licensure, New York State

2002                Medical Licensure, California

 

6.         Military Service:

 

Military service in the Swedish Army during 1969, 1972, 1983, 1984 and 1986. Served as Medical Officer 1984 and 1986. 

Rank: Fänrik (corresponding to Ensign).

 

7.         Professional organizations and societies:

 

Swedish Society of Clinical Chemistry

European Society of Clinical Investigation

American Heart Association, Council on Arteriosclerosis, Thrombosis and Vascular Biology

American Association of Clinical Chemistry

Endocrine Society

American Society of Clinical Nutrition

 

8.         Academic appointments:

 

1986-1990       Assistant Professor, (Avdelningsläkare), Department of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden

1990-1993       Associate Professor (Biträdande överläkare), Department of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden

1993-2000       Associate Professor of Medicine, College of Physicians and Surgeons of Columbia University, New York, N.Y.

1995-2002       Associate Director, General Clinical Research Center, New York Presbyterian Hospital, New York, NY.

2000-2002       Professor of Medicine, College of Physicians and Surgeons of Columbia University, New York, NY.

2002-2006       Director, General Clinical Research Center, University of California Davis / VA Northern California Health Center, CA

2002-present    Professor of Medicine, University of California Davis, CA.

2004-2006       Assistant Dean for Clinical Research, University of California Davis, CA

2006-present    Associate Dean for Cinical and Translational Research, University of California, Davis

2006-present    Director, Clinical and Translational Science Center, University of California, Davis

 

 

9.         Hospital appointments:

 

1986-1990       Associate Director, Hormone, Research and Development Laboratory,

                        Huddinge University Hospital, Stockholm, Sweden

1986-1993       Director, Lipoprotein Laboratory, Huddinge University Hospital, Stockholm, Sweden

1990-1993       Director, Emergency Chemistry Laboratory, Routine Chemistry Laboratory and Center for Outpatient clinical laboratory analysis and Functional tests, Huddinge University Hospital, Stockholm, Sweden.

1997-2000             Associate Attending Physician, New York Presbyterian Hospital, New York, NY.

2000-2002             Attending Physician, New York Presbyterian Hospital, New York, NY

2002-               Attending Physician, UC Davis Medical Center, Sacramento, CA

 

10.              Honors

 

1980-current    Docent in Medical and Physiological Chemistry, University of Uppsala.  (This title is required for senior teaching positions in Swedish Medical Schools and is awarded by a University Docent Committee based on a report of the individual's research and teaching activities by a senior scientist from another University.

 

1990                Appointed by the Faculty of Medicine, University of Uppsala, to be "opponent" (examinator on Ph.D. thesis during public thesis defense) for Steven Martin, Department of Medical and Physiological Chemistry, University of Uppsala on his thesis:   Phosphorylation of plasma proteins.

 

1994-1999             Established Scientist, American Heart Association, New York City Affiliate

1995        Invited Speaker, Neurological Society Meeting, Seattle, WA

1996        Invited Speaker, AHA National Stroke Meeting, San Antonio, TX

2000    Invited Speaker, XIIth International Symposium on Atherosclerosis, Stockholm, Sweden

2000    Invited Speaker, Gordon Research Conference on Lipoprotein Metabolism

2001    Invited Speaker, American Heart Association annual meeting Anaheim, CA

2001    Invited Speaker, 1st International HIV meeting, Buenos Aires, Argentina

2001        Invited Speaker, CPCRA Scientific meeting, Washington DC

2002        Internal Medicine Grand Rounds, UC Davis

2002    Endocrinology Grand Rounds, UCSF

2003    Invited Speaker, AHA National Stroke Meeting, Phoenix, AZ

2003        Invited Speaker, AACC National Meeting, Philadelphia, PA

2004        Invited Speaker, FASEB Meeting, Washington DC

2004    Invited Speaker, Endocrinology Grand Rounds, Oregon Health Sciences Ctr, Portland, OR

2004    Invited Speaker, Endocrinology Grand Rounds, Wayne State University, Detriot, MI

2005    Invited Speaker, Endocrinology Grand Rounds, Univeristy California, San Diego, San Diego, CA

2005        Invited Speaker, 12th Conference on Retroviruses and Opportunistic Infections, Boston

2006        Invited Speaker, NIH Lipoprotein Metabolism in HIV/HAART

2006    Invited speaker, Nutrition and Vascular Disease conference, Palm Springs, CA

2007        Invited speaker, Endocrinology Grand Rounds, University of Arkansas, Little Rock,AR

2007    Invited speaker, Womens Health Conference, Kailua, HI

2007    Endocrine Society, Outstanding Reviewer Recognition Award

2007    Invited Speaker, 39th Meeting of the Japanese Atherosclerotic Society, Osaka, Japan

2007    Invited speaker, Medicine Grand Rounds, Yamagata University, Yamagata, Japan

2007    Invited speaker, Pathology Grand Rounds, Yamanashi University, Kofu, Japan

2007    Invited speaker, Pediatrics Grand Round, Georgetown University, Washington DC

2007    Internal Medicine Grand Rounds, UC Davis

2007    Frederic C. Bartter Visiting Professor, UT San Antonio

2007    Invited speaker, Medicine Grand Rounds, UT San Antonio

2008        Invited Speaker, FASEB Meeting, San Diego, CA

2008    Invited presenter, NCRR Council, NIH

 

11.       Fellowship and grant support:

 

Fellowships:

 

1983-1985       Career Development Award, Swedish Medical Research Council

 

1986                Visiting Scientist at the Food and Agriculture Council, Babraham, Cambridge, United Kingdom 1986.  (Supported by a grant from the Swedish Institute).

 

1987-1988       Visiting Scientist at the Division of Endocrinology/Metabolism, Department of Medicine, University of California San Diego, La Jolla, California, USA 1987-88 (supported by grants from the Throne-Holst Foundation, the Swedish Medical Research Foundation and The Swedish Society of Medicine).

 

Research grants:

 

Past:

Principal Investigator:

Tore Nilsson Foundation for young scientists: 1983-85

Grants from the Karolinska Institute: 1983-1993

Swedish Hoechst Foundation: 1990-1992

Ostermans Foundation: 1992-1993

Nordic Insulin Foundation: 1990-1994

Swedish Medical Research Council: 1992-1994

Trygg-Hansa Foundation: 1993-1994

Grant-in-aid, American Heart Association, New York City Affiliate, 1994-1997

NIH: Lipoprotein and adipose tissue metabolism in HIV, supplemental grant 2002-2003

NIH: Nutrition Academic Award, 2000-2005

NIH: Lipoprotein and adipose tissue metabolism in HIV, 2000-2007

NIH: General Clinical Research Center, 2004-2006 (Program Director)

 

Co-Investigator:

Swedish Medical Research Council (P.I. Bo Angelin) 1984-1993

King Gustaf V and Queen Victoria Foundation (P.I. Bo Angelin) 1986-90

Grants from the Rockefeller University (P.I. Attallah Kappas) 1986-87

NIH: Multicenter studies of diet and lipoproteins in humans (P.I. Henry Ginsberg) 1992-96

NIH: Genetic and biochemical markers for premature atherosclerosis (P.I. Steven Shea) 1994-99

NIH: Epidemiology of dementia in an urban community (P.I. Richard Mayeux) 1994-99

USDA: Studies on how tissue pools of vitamin A are generated (P.I. William Blaner) 1996-1998

NIH: Diabetes, lipoproteins and accelerated vascular disease (P.I. Henry Ginsberg) 1996-2001

NIH: General Clinical Research Center (P.I. Henry Ginsberg) 1999-2002

NIH: SCOR in Vascular Biology (P.I. Alan Tall), 1999-2002

NIH: Aortic arch placques and stroke in an ethnically mixed population (P.I. Marco DiTullio),1997-2002

NIH: Clinical Nutrition Research Unit (Halsted, CH), 1999-2004

 

Current:

Principal Investigator:

NIH: Regulation of lipoprotein (a) metabolism in humans, 2000-present

NIH: Clinical and Translational Science Center, 2006-2011

NIH: CTSC Predoctoral training grant, 2006-2011

NIH: CTSC Career development training grant, 2006-2011

 

Co-Investigator:

NIH: Interactions of Lipoproteins with the Artery Wall (Rutledge, JC PI), 2004-2008

 

11.              Departmental, University and National Committees

 

1996-2002       Member, PhD Subcommittee on Nutrition, Institute of Human Nutrition, College of Physicians and Surgeons of Columbia University.

2000-2001       Chairman, Committee revising Master’s Program in Nutrition, Institute of Human Nutrition

2000-2002       Member, Study section Northeast Affiliate Study Group, American Heart Association

2000-2001             President, New York Lipid and Vascular Biology Research Club

2001                Ad hoc Reviewer, NIAID, NIH, Special Emphasis Panel, Centers for AIDS Research

2002                Reviewer, NIH site visit committee, NCRR (Cleveland Clinic)

2002-2003      Co-Chair, Behavioral Science, Epidemiology and Prevention Study Section, American Heart Association

2003-2005      Chair, Research & Development Committee,  VA Northern California HCS

2003-current   Member, Graduate Group in Nutrition, UC Davis

2003-2006       Member, Committee on Cardiovascular Disease, ACTU

2003                Reviewer, NIH site visit committee, NCRR (UCSF)

2003-current    Member, Advisory Committee, Primate Center, UC Davis

2004-2006      Chair, Behavioral Science, Epidemiology and Prevention Study Section, American Heart Association

2004-2006      Interim Chair, Graduate Group in Clinical Research, UC Davis

2005                Ad hoc member, NIH program project review committee, NIDDK.

2006-present   Chartered member, AIDS Clinical Studies and Epidemiology Study Section, NIAID.

2007                Review committee, New York State for Ph D program, University of Rochester

2007                Member, CTSA External Advisory Board, University of New Mexico

2007                Member, CTSA External Advisory Board, University of Arkansas

2007                Member, CTSA External Advisory Board, University of North Dakota

2007                Member,  American Heart Association Science Classification Task Force

2007-present   Co-Chair, CTSA Consortium Oversight Committee, NIH

2007                Member, Search committee, Chief of Staff, VA Northern California HCS

2007               Ad hoc Member, Review committee, British/Irish Medical Research Council

2007               Member, Review panel, NIH Director’s New Investigator Award

2007-present  Member, Peer Review Committee, American Heart Association

2007               Member, Review committee, New York State for MS program, Columbia University

2008               Member, CTSA External Advisory Board, Columbia University, New York

2008               Member, Review panel, NIH Director’s New Investigator Award

 

 

12.       Teaching experiences and responsibilities

 

1970-1977 - Amanuens and Assistent (tutor) at the Departments of Anatomy and Medical and   Physiological Chemistry, University of Uppsala, Sweden.  (Instructor for medical students in the courses in Anatomy and Medical Chemistry during their first two years of Medical School).

1982-1984 - Clinical instruction and teaching for medical students in Internal Medicine,   Emergency Care and Gastroenterology during the course in Internal Medicine at the Department of Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.

 

1982-1985 - Teacher for medical students in Clinical Chemistry (compulsory course in the School of Medicine at the Karolinska Institute).  The courses are given twice yearly and teaching responsibilities included: 1) Lectures on:  Plasma proteins in disease, Liver function tests, Haematology, Gastrointestinal disease. 2) Seminars on:  Plasma proteins, Lipid disorders, Liver diseases, Kidney diseases, Emergency care medicine. 3) Clinical conferences on Liver disease and Thyroid tests. 4) Responsibility for oral examination in Clinical Chemistry, required for M.D. exam.

 

1985-1990 - Teacher and co-organizer of research instruction courses at the Karolinska Institute on: Clinical disorders of lipid metabolism 1985 and 1990, Biochemical atherosclerosis research 1988.

 

1994-2002 - Teacher for 4th year medical students in the courses "Clinical Pharmacology and Therapeutics" and “Clinical Practice IV: Return to the Classroom Sessions” at College of Physicians and Surgeons of Columbia University

 

1996-2002 - Teacher for 1st year medical students in the course Science Basic to the Practice of Medicine (Two lectures on ‘Synthesis and oxidation of fuels: carbohydrates, lipids and the citric acid cycle’), and in the Nutrition course (One lecture on ‘Diet and cardiovascular disease’), part of Clinical Practice I at College of Physicians and Surgeons of Columbia University.

 

1999-2002 - Preceptorship in clinical medicine for 3rd year medical students, College of Physicians and Surgeons of Columbia University

Attending physician teaching rounds, New York Presbyterian Hospital

 

2000-2002 - P.I. and Director, Nutrition Academic Award (NIH), Columbia University. Restructuring of nutrition teaching program.

 

2002-present - Instructor for 2nd year medical students in the courses in Endocrinology and Nutrition (Lectures on Lipids and cardiovascular disease and Diets and cardiovascular disease), Instructor in the Doctoring course and Instructor in the course “Study design and clinical research” for postgraduate fellows and faculty, UC Davis

 

2004-present - Teacher, Mentored Clinical Research Training Program and T32 Program, University of California, Davis

 

2005    Teacher, Methods in Epidemiologic, Clinical & Operations Research course, American Thoracic Society, Quito, Ecuador.

 

2006-present    Director, T32 training grant

 

2006    Teacher, Methods in Epidemiologic, Clinical & Operations Research course, American Thoracic Society, Sao Paulo, Brazil.

 

2007    Teacher, Methods in Epidemiologic, Clinical & Operations Research course, American Thoracic Society, Quinamavida, Chile.

 

Ph.D. - thesis sponsor for:

Sverker Ericsson, Ph.D. exam 1992, Karolinska Institute, Stockholm

Ayman AL-Shurbaji, Ph.D. exam 1993, Karolinska Institute, Stockholm

Furcy Paultre, Ph.D. exam 2000, Institute of Human Nutrition, Columbia University

Jill Rubin, Ph D exam 2002, Institute of Human Nutrition, Columbia University

 

Ph.D. - thesis examination committee:

Johan Frostegård, Ph.D. 1992, Karolinska Institute, Stockholm

Mary Gamble, Ph D 1999, Institute of Human Nutrition, Columbia University.

Carmen Isasi, Ph.D. 2001, School of Public Health, Columbia University

 

M.Sc. thesis sponsor for:

Ting Kuang, 1997, Institute of Human Nutrition, Columbia University

Martin Stern, 1999, Institute of Human Nutrition, Columbia University

Jackson Gustave, 2000, Institute of Human Nutrition, Columbia University

Elizabeth Todd, 2001, Institute of Human Nutrition, Columbia University

Jeffrey Jones, 2001, Institute of Human Nutrition, Columbia University

Neda Moghrel, 2006, Nutrition Graduate Group, UC Davis

 

M.Sc. Advisory committee for:

Nicholas Kenyon, M.D., Associate Professor, UC Davis

Michelle Apperson, M.D., Ph.D., Assistant Professor, UC Davis

Valentina Medici, M.D., Assistant Professor, UC Davis

Erdembileg Anuurad, M.D., Ph.D., Postdoctoral fellow, UC Davis

 

Intel project sponsor for:

Andrew Simon, 2001, Byram Hills High School, Armonk, NY, Intel Semifinalist

 

 

14.       Other professional activities.

 

Editorial Board Memberships:

The Journal of Clinical Endocrinology and Metabolism, 2002-2006; 2008-2012

American Journal of Clinical Nutrition, 2002-present

Arteriosclerosis, Thrombosis and Vascular Biology, 2003-present

Current Nutrition Reviews 2005-present

 

Ad hoc reviewer for:

Arteriosclerosis, Thrombosis and Vascular Biology; Atherosclerosis; American Journal of Clinical Nutrition; Annals of Internal Medicine; Biochimica Biophysica Acta; Circulation; Diabetes Care; Journal of Clinical Investigation; Journal of Clinical Endocrinology and Metabolism; Journal of Clinical and Laboratory Medicine; Journal of Lipid Research; Journal of Internal Medicine; Nature; New England Journal of Medicine; Kidney International;  Metabolism; Obesity Research; Translational Research.

 

PUBLICATIONS

 

A.  Original, peer-reviewed articles.

 

1.      Ljungström O, Berglund L, Hjelmquist G, Humble E, Engström L.  Cyclic 3',5'-AMP- stimulated Phosphorylation of Protein Fractions from Rat-liver Cell Sap on Incubation with (y-32P)ATP.  Upsala Journal of Medical Science (1974), 79: 129-137.

 

2.      Humble E, Berglund L, Titanji V, Ljungström O, Edlund B, Zetterqvist Ö, Engström L.  Non-dependence on native structure of pig liver pyruvate kinase when used as a substrate for cyclic 3',5'-AMP-stimulated protein kinase. Biochemical and Biophysical Research Communications (1975), 66: 614-621.

 

3.      Zetterqvist Ö, Ragnarsson U, Humble E, Berglund L, Engström L.  The minimum substrate of cyclic AMP-stimulated protein kinase, as studied by synthetic peptides representing the phosphorylation site of pyruvate kinase (type L) of rat liver.  Biochemical and Biophysical Research Communications (1976), 70: 696-703.

 

4.      Ljungström O, Berglund L, Engström L. Studies on the Kinetic Effects of Adenosine-3':5'-Monophosphate-Dependent Phosphorylation of purified pig liver pyruvate kinase type L.  European Journal of Biochemistry (1976), 68: 497-506.

 

5.      Berglund L, Ljungström O, Engström L.  Studies on the Cyclic 3':5'-AMP-stimulated Pig Liver Protein Kinase Reaction with Pyruvate Kinase as Substrate*.  Journal of Biological Chemistry (1977), 252: 613-619.

 

6.      Berglund L, Ljungström O, Engström L. Purification and Characterization of Pig Kidney Pyruvate Kinase (Type A). Journal of Biological Chemistry (1977), 252: 6108-6111.

 

7.      Berglund L.  Phosphorylation of rat kidney pyruvate kinase type L by cyclic 3',5'-AMP-dependent protein kinase.  Biochimica et Biophysica Acta (1978), 524: 68-77.

 

8.      Berglund L, Humble E.  Kinetic properties of pig pyruvate kinases type A from kidney and type M from muscle¹.  Archives of Biochemistry and Biophysics (1979), 195: 347-361.

 

9.      Berglund L, Khoo JC, Jensen D, Steinberg D. Resolution of hormone-sensitive triglyceride/diglyceride lipase from monoglyceride lipase of chicken adipose tissue*. Journal of Biological Chemistry (1980), 225: 5420-5428.

 

10.  Khoo, JC, Berglund L, Jensen, D, Steinberg, D. Hormone-sensitive lipase of rat adipose tissue: Correlation of activity with a protein of molecular weight 84 000.  Biochimica et Biophysica Acta (1980), 619: 440-444.

11.  Berglund, L., Björkhem I, Einarsson K. Apparent phosphorylation-dephosphorylation of soluble phosphatidic acid phosphatase in rat liver.  Biochemical and Biophysical Research Communications (1982), 105: 288-295.

 

12.  Wadstein, J., Nilsson K-H, Berglund L, Skude G. A possible role of antithrombin III in venous thrombosis among alcoholics.  Drug and Alcohol Dependence (1982), 9: 177-179.

 

13.  Berglund L, Björkhem I, Angelin B, Einarsson K.  Evidence against in vitro modulation of rat liver cholesterol 7 α-hydroxylase activity by phosphorylation-dephosphorylation:  Comparison with Hydroxymethlglutaryl  CoA reductase.  Acta Chemica Scandinavia (1986), B40: 457-461.

 

14.  Berglund L, Angelin B.  Gravad fisk indirect orsak till grav anemi och viktnedgång (Grave anemia and weight loss in a previously healthy 37 year-old male).' Läkartidningen (Bulletin of the Swedish Medical Association) (1986), 83: 496.

 

15.  Björkhem I, Berglund L. Stimulatory effect of mevinolin on rat liver phosphatidic acid phosphatase.  Biochimica et Biophysica Acta (1987), 920: 20-25.

 

16.  Eriksson M, Lantz B, Berglund L , Angelin B. Plasma exchange in a patient with heterozygous familial hypercholesterolemia resistant to drug therapy. Acta Medica Scandinavica (1987), 221: 317-320.

 

17.  Berglund L, Angelin B, Blomstrand R, Drummond G, Kappas A. Sn-protoporphyrin lowers serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and potently inhibits hepatic heme oxygenase avtivity in normal human subjects. Hepatology (1988), 8: 625-631.

 

18.  Berglund L, Björkhem I, Angelin B, Einarsson K. Activation of rat liver cytosolic phosphatidic acid phosphatase by nucleoside diphosphates. Biochimica et Biophysica Acta (1989), 1002: 382-387.

 

19.  Eriksson M, Berg B, Berglund L, Lantz B, Angelin B. Lipid lowering in severe familial hypercholesterolemia:  Efficacy and safety of a new regenerating system for selective apheresis of apolipoprotein B-containing lipoproteins.  Journal of Internal Medicine (1989), 225: 29-34.

 

20.  Henriksson P, Stamberger M, Eriksson M, Rudling M, Diczfalusy U, Berglund L, Angelin B.  Oestrogen-induced changes in lipoprotein metabolism:  Role of prevention of atherosclerosis in the cholesterol-fed rabbit.  European Journal of Clinical Investigation (1989), 19, 395-403.

 

21.  Emtestam, L, Berglund L, Angelin B, Drummond GS, Kappas A. TIN-protoporphyrin and long wave length ultraviolet light in treatment  of psoriasis.  Lancet (1989), i: 1231-1233.

22.  Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of Estrogen on low density lipoprotein matabolism in males.  Journal of Clinical Investigation (1989), 84: 802-810.

 

23.  Al-Shurbaji, A, Berglund L. Rat adipose tissue phosphatidic acid phosphatase: Lack of effect of nucleotides on cytosolic enzyme activity.  Acta Chemica Scandinavica (1989), 43: 680-683.

 

24.  Ahnve S, Angelin B, Edhag O, Berglund L.  Early determination of serum lipids and apolipoproteins in acute myocardial infarction:  possibility for immediate intervention.  Journal of Internal Medicine (1989), 226: 297-301.

 

25.  Berglund L, Sharkey MF, Elam RL, Witztum JL. Effect of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism.  Journal of Lipid Research (1989), 30, 1591-1600.

 

26.  Henriksson P, Eriksson M, Ericsson S, Rudling M, Stege R, Berglund L, Angelin B.  Hypocholesterolaemia and Increased elimination of low-density lipoproteins in metastatic cancer of the prostate.  Lancet (1989), ii: 1178-1180.

 

27.  Al-Shurbaji, A, Berglund L, Björkhem I. The effect of acipimox on triacylglycerol metabolism in rats.  Scandinavian Journal of Clinical and Laboratory Investigation (1990), 50: 203-208.

 

28.  Berglund L, Angelin B, Hultcrantz R, Einarsson K, Emtestam L, Drummond G, Kappas A.  Studies with haeme oxygenase inhobirtor Sn-protoporphyrin in patients with primary biliary cirrhosis and idiopathic haemochromatosis.  Gut (1990), 31: 899-904.

 

29.  Wiklund, O, Angelin B, Fager G, Eriksson M, Olofsson S-O, Berglund L, Lindén T, Sjöberg A, Bondjers G.  Treatment of familial hypercholesterolaemia: A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Journal of Internal Medicine (1990), 228: 241-247.

 

30.  Wiklund O, Angelin B, Olofsson S-O, Eriksson M, Fager G, Berglund L, Bondjers G. Apoloiprotein(a) and ischaemic heart disease in familial hypercholesterolemia.  Lancet (1990), 335: 1360-1363.

 

31.  Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B.  Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.  New England Journal of Medicine (1990), 323, 224-228.

 

32.  Björkhem I, Henriksson A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arteriosclerosis and Thrombosis (1991), 11: 15-22.

33.  Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. Journal of Clinical Investigation (1991), 87: 591-596.

 

34.  Sjöberg S, Gjötterberg M, Berglund L, Möller E, Östman, J. Residual C-peptide excretion is associated with a better long-term glycaemic control and slower progress of retinopathy in type I (Insulin-dependent) diabetes mellitus.  Journal of Diabetic Complications (1991),5: 18-22.

 

35.  Ödman B, Ericsson S, Lindmark M, Berglund L, Angelin B. Gemfibrozil in familial combined hyperlipidemia: Effect of added low-dose cholestyramine on plasma and biliary lipids.  European Journal of Clinical Investigation (1991), 21: 344-349.

 

36.  Elmberger G, Kalen A, Lund E, Reihnér E, Eriksson M, Berglund L, Angelin B, Dallner G.  Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.  Journal of Lipid Research (1991), 32: 935-940.

 

37.  Eriksson M, Angelin B, Henriksson P, Ericsson S, Vitols S, Berglund L. Metabolism of lipoprotein remnants in humans: Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arteriosclerosis and Thrombosis (1991), 11: 827-837.

 

38.  Al-Shurbaji A, Larsson-Backström C, Berglund L, Eggertsen G, Björkhem I. Effect of n-3 fatty acids on the key enzymes involved in cholesterol and triglyceride turnover in rat liver.  Lipids (1991), 26: 385-389.

 

39.  Humble E, Berglund L. Stimulation and inhibition of the activity of rat liver cytosolic phosphatidate phosphohydrolase by various phospholipids.  Journal of Lipid Research (1991), 32, 1869-1872.

 

40.  Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels:  opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.  Journal of Clinical Investigation (1992), 89: 1166-1171.

 

41.  Ericsson, S, M Eriksson, L Berglund, B Angelin. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia:  Effect of acipimox therapy.  Journal of Internal Medicine (1992), 232: 313-320.

 

42.  Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Lindén T, Miettinen T, Ödman B, Olofsson S-O, Saarinen I, Sipilä R, Sjöström P, Kron P, Vanhanen H, Wright I. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.  American Journal of Medicine (1993), 94: 13-20.

 

43.  Berglund L, Wiklund O, Eggertsen G, Olofsson S-O, Eriksson M, Lindén T, Bondjers G, Angelin B. Apolipoprotein E phenotypes in familial hypercholesterolemia: Importance for expression of disease and response to therapy. Journal of Internal Medicine (1993), 233: 173-178.

 

44.  Emtestam L, Angelin B, Berglund L, Drummond GS, Kappas A.  Photodynamic properties of Sn-protoporphyrin:  Clinical investigations and phototesting in human subjects. Acta Dermatologica Venerologica (1993), 73: 26-30.

 

45.  Freyschuss A, Stiko-Rahm, A, Swedenborg, J, Henriksson P, Björkhem I, Berglund L, Nilsson J. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. Journal of Clinical Investigation (1993), 91:1282-1288.

 

46.  Skorve J, Al-Shurbaji A, Asiedu D, Björkhem I, Berglund L, Berge RK. On the mechanism of the hypolipidemic effect of sulfur-substituted hexadecanedioic acid (3-thiadicarboxylic acid) in normolipidemic rats.  Journal of Lipid Research (1993), 34: 1177-1185.

 

47.  Humble E, Berglund L. Studies on triglyceride metabolism: phosphatidate phosphohydrolase from guinea pig Harderian gland.  Scandinavian Journal of Clinical and Laboratory Investigation (1993), 53: 493-498.

 

48.  Olivecrona H, Ericsson S, Berglund L, Angelin B. Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment.  BMJ (1993), 306: 1726-1727.

 

49.  Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population:  Variation of allele frequency with age and relation to serum lipid concentrations.  Clinical Chemistry (1993), 39: 2125-2129.

 

50.  Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome.  Kidney International (1993), 44: 1116-1123.

 

51.  Al-Shurbaji A, Skorve J, Berge RK, Rudling M, Björkhem I, Berglund L. Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis. Arteriosclerosis and Thrombosis (1993), 13: 1580-1586.

 

52.  Eriksson M, Berglund L, Gabrielsson J, Lantz B, Angelin B. Non-steady state kinetics of low density lipoproteins in man:  Studies after plasma exchange in healthy subjects and patients with familial hypercholesterolaemia.  European Journal of Clinical Investigation (1993), 23: 746-752.

 

53.  Berglund L, Beltz WF, Elam RL, Witztum JL.  Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. Journal of Lipid Research (1994), 35: 956-965.

54.  Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Björkhem I, Bergström J. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids:  A prospective, double-blind, randomized study.  Clinical Nephrology (1994), 41: 183-190.

 

55.  Lannfelt L, Lilius L, Nasatase M, Viitanen M, Frataglioni L, Eggertsen G, Berglund L, Angelin B, Linder L, Winblad B, Basun H. Lack of association between apolipoprotein E allele E 4 and sporadic Alzheimer's disease.  Neuroscience Letters (1994), 169: 175-178.

 

56.  Xiu RJ, Freyschuss A, Ying X, Berglund L, Henriksson P, Björkhem I. The antioxidant butylated hydroxytoluene prevents early cholesterol-induced microcirculatory changes in rabbits.  Journal of Clinical Investigation  (1994), 93: 2732-2737.

 

57.  Bröijersen A, Eriksson M, Larsson PT, Beck O, Berglund L, Angelin B, Hjemdahl P.  Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familiar hypercholesterolemia.  European Journal of Clinical Investigation (1994), 24, 488-498.

 

58.  Humble E, Al-Shurbaji A, Lund E, Berglund L. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids:  Effect of HMG-CoA reductase inhibitors.  Biochimica et Biophysica Acta  (1994), 1214: 32-38.

 

59.  Eggertsen G, Eriksson M, Wiklund O, Iitiä A, Olofsson S-O, Angelin B, Berglund L. Time-resolved fluorometry in the genetic diagnosis of familiar defective apolipoprotein B-100.   Journal of Lipid Research (1994), 35: 1505-1508.

 

60.  Nemeth A, Veress B, Myrdal U, Rudling M, Berglund L, Angelin B. Studies on lipoprotein metabolism in a family with jejunal chylomicron retention.  European Journal of Clinical Investigation (1995), 25: 271-280.

 

61.  Ståhlberg D, Reihnér E, Rudling M, Berglund L, Einarsson K, Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7a-hydroxylase.  Hepatology (1995), 21: 1025-1030.

 

62.  Asiedu DK, Al-Shurbaji A, Rustan AC, Björkhem I, Berglund L, Berge RK. Hepatic fatty acid metabolism as a determinant of plasma and liver triglyceride levels: Studies on tetradecylthioacetic and tetradecylthiopropionic acids. European Journal of Biochemistry  (1995), 227: 715-722.

 

63.  Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein (a) levels: Contrasting effects of growth hormone and insulin-like growth factor-I. Arteriosclerosis, Thrombosis and Vascular Biology (1995), 15: 847-849.

 

64.  Heimbürger O, Stenvinkel P, Berglund L, Tranaeus A, Lindholm B. Increased plasma lipoprotein (a) in Continuous Ambulatory Peritoneal Dialysis is related to peritoneal transport of proteins and glucose. Nephron (1996), 72: 135-144.

 

65.  Tegelman R, Åberg T, Eklöf R, Pousette Å, Carlström K, Berglund L. Influence of a diet regimen on glucose homeostasis and serum lipid levels in male elite athletes. Metabolism, (1996), 45: 435-441.

 

66.  Jogestrand T, Fehrman-Ekholm I, Angelin B, Berglund L, Gäbel H. Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. Journal of Internal Medicine, (1996), 239: 177-180.

 

67.  Berglund L, Carlström K, Stege R, Gottlieb C, Eriksson M, Angelin B, Henriksson P. Hormonal regulation of serum lipoprotein (a) levels: Effects of parenteral administration of estrogen or testosterone in males*. Journal of Clinical Endocrinology and Metabolism (1996), 81: 2633-2637.

 

68.  Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low-density lipoprotein metabolism and its association to plasma Lipoprotein(a) in the nephrotic syndrome. European Journal of Clinical Investigation (1997), 27: 169-177.

 

69.  Eggertsen G, Heimbürger O, Stenvinkel P, Berglund L. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrology Dialysis Transplantation (1997), 12: 141-144.

 

70.  Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein (a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arteriosclerosis, Thrombosis and Vascular Biology (1997), 17: 1822-1829.

 

71.  Sacco RL, Roberts JK, Boden-Albala B, Gu Q, Lin IF, Kargman DE, Berglund L, Hauser WA, Shea S, Paik MC. Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population: The Northern Manhattan Stroke Study. Stroke (1997), 28: 929-935.

 

72.  Pillarisetti S, Paka S, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a): Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. Journal of Clinical Investigation (1997), 100: 867-874.

 

73.  AL-Shurbaji A, Berglund L, Berge RK, Cederblad G, Humble E. On the interrelationship between hepatic carnitine, fatty acid oxidation, and triglyceride biosynthesis in nephrosis. Lipids (1997), 32: 847-852.

 

74.  Pablos-Mendez A, Mayeux R, Ngai C, Shea S, Berglund L. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arteriosclerosis, Thrombosis and Vascular Biology (1997), 17: 3534-3541.

75.  Ericsson S, Berglund L, Frostegård J, Einarsson K, Angelin B. Influence of age on low density lipoprotein metabolism: Effects of cholestyramine treatment in young and old healthy male subjects. Journal of Internal Medicine (1997), 242: 329-337.

 

76.  Held C, Hjemdahl P, Rehnquist N, Bjorkander I, Forslund L, Berglund L, Angelin B. Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: Results from the Angina Prognosis Study in Stockholm (APSIS). Atherosclerosis (1997), 135: 109-118.

 

77.  Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. Journal of Cardiovascular Risk (1997), 4: 385-391.

 

78.  Berglund L, Witztum JL, Galeano NF, Khouw AS, Ginsberg HN, Ramakrishnan R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. Journal of Lipid Research (1998), 39: 913-924.

 

79.  Stenvinkel P, Heimburger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney International (1998), 53: 1336-1342.

 

80.  Al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L. Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids (1998), 33: 165-169.

 

81.  Kargman DE, Tuck CH, Berglund L, Lin IF, Thompson EV, Mukherjee RS, Jones J, Boden-Albala B, Paik MC, Sacco, RL. Lipid and lipoprotein levels remain stable in acute ischemic strok: The Northern Manhattan Stroke Study. Atherosclerosis (1998), 139: 391-399.

 

82.  Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, Tycko B, Leff T, Shachter NS. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. Journal of Lipid Research (1999), 40: 50-58.

 

83.  Redlich CA, Chung JS, Cullen MR, Blaner WS, van Bennekum AM, Berglund L. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis (1999), 143: 427-434.

 

84.  Barth JA, Deckelbaum RJ, Starc TJ, Shea S, Mosca L, Berglund L. Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: Relationship to lipoprotein (a) and Low-Density Lipoprotein cholesterol levels. Journal of Clinical and Laboratory Medicine (1999), 133: 237-244.

85.  Werynski A, Nahorski Z, Berglund L, Ericsson S, Angelin B, Eriksson M. Evidence of circadian rhythm in Low-Density Lipoprotein apoB catabolism and its impact on estimation of kinetic parameters. European Journal of Clinical Investigation (1999), 29: 291-300.

 

86.  Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney International (1999), 55: 1899-1911.

 

87.  Berglund L, Galbraith RA, Emtestam L, Drummond GS, Angelin B, Kappas A. Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute phase reactants in man. Pharmacology (1999); 59: 51-56.

 

88.  Moroney JT, Tang M-X, Berglund L, Small S, Merchant C, Bell K, Stern Y, Mayeux R. Low-density lipoprotein cholesterol and the risk for dementia after stroke. JAMA (1999), 282: 254-260.

 

89.  Shea S, Isasi CR, Couch S, Starc TJ, Tracy RP, Deckelbaum R, Talmud P, Berglund L, Humphries SE. Relationships of plasma fibrinogen level in children to measures of obesity, the (G-455®A) mutation of the b-fibrinogen promotor, and family history of ischemic heart disease: The Columbia BioMarkers Study. American Journal of Epidemiology (1999), 150: 737-746.

 

90.  Romas SN, Tang M-X, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology (1999), 53: 517-521.

 

91.  Berglund L, Oliver EH, Fontanez NF, Holleran S, Matthews K, Roheim PS, Ginsberg HN, Ramakrishnan R, Lefevre M for the DELTA Investigators. HDL subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects ¹ֿ³ . American Journal of Clinical Nutrition (1999), 70: 992-1000.

 

92.  Isasi CR, Starc T, Tracy RP, Deckelbaum RJ, Talmud P, Berglund L, Humphries SE, Shea S. Inverse association of physical fitness with plasma fibrinogen level in children: the Columbia University BioMarkers Study. American Journal of Epidemiology (2000), 152: 212-218.

 

93.  Sousa MM, Berglund L, Saraiva MJ. Transthyretin in high density lipoproteins: association with apolipoprotein A-I. Journal of Lipid Research (2000), 41: 58-65.

 

94.  Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing*. Journal of Clinical Endocrinology and Metabolism (2000), 85: 995-1000.

95.  Isasi CR, Couch SC, Deckelbaum RJ, Starc TJ, Otvos JD, Shea S, Berglund L. Apolipoprotein e2 allele is associated with an anti-atherogenic lipoprotein profile in children: The Columbia University Biomarkers Study. Pediatrics (2000), 106: 568-575.

 

96.  Fard A, Tuck CH, Donis JA, Sciacca R, DiTullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in type 2 diabetes. Arteriosclerosis, Thrombosis and Vascular Biology (2000), 20: 2039-2044.

 

97.  Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P. Hand-grip muscle strength, lean body mass and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. American Journal of Kidney Disease (2000), 36: 1213-1225.

 

98.  Couch SC, Isasi CR, Karmally W, Blaner WS, Starc TJ, Kaluski D, Deckelbaum RJ, Ginsberg HN, Shea S, Berglund L. Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. American Journal of Clinical Nutrition (2000), 72: 1119-1127.

 

99.  Paultre F, Pearson TA, Weil HFC, Tuck CH, Myerson M, Rubin J, Francis CK, Marx H, Philbin E, Reed RG, Berglund L. High levels of lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arteriosclerosis, Thrombosis and Vascular Biology (2000), 20: 2619-2624.

 

100.          Jiang XJ, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arteriosclerosis, Thrombosis and Vascular Biology (2000), 20: 2614-2618.

 

101.          Gamble MV, Ramakrishnan R, Palafox NA, Briand K, Berglund L, Blaner WS. Retinol-binding protein as a surrogate measure for serum retinol: Studies in vitamin A-deficient children from the Republic of the Marshall Islands. American Journal of Clinical Nutrition (2001), 73: 594-601.

 

102.          Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin I-F, Cheng JF, Paik MC, Shea S, Berglund L. High density lipoprotein cholesterol for ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA (2001), 285: 2729-2735.

 

103.          Talmud PJ, Berglund L, Hawe EM, Waterworth DM, Isasi CR, Deckelbaum RJ, Starc T, Ginsberg HN, Humphries SE, Shea S. Age-related effects of genetic variation lipid levels. The Columbia University BioMarkers Study. Pediatrics (2001), 108: e50 (http://www.pediatrics.org/cgi/content/full/108/3/e50).

104.          Rubin J, Pearson TA, Reed RG, Berglund L. Fluorescence-based, nonradioactive method for efficient detection of the pentanucleotide repeat (TTTTA)n polymorphism in the apolipoprotein(a) gene. Clinical Chemistry (2001), 47: 1758-1762.

 

105.          Freyschuss A, Al-Shurbaji A, Bjorkhem I, Babiker A, Diczfalusy U, Berglund L, Henriksson P. On the anti-atherogenic effect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions. Biochim Biophys Acta (2001), 1534: 129-138.

 

106.          Rodriguez C, Pablos-Mendez A, Palmas W, Lantigua R, Mayeux R, Berglund L. Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and non-Hispanic Caucasians ≥ 65 years of age and living in New York City. American Journal of Cardiology (2002), 89: 178-183.

 

107.          Paultre F, Tuck CH, Boden-Albala B, Kargman DE, Todd E, Jones J, Paik MC, Sacco RL, Berglund L. Relation of apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arteriosclerosis, Thrombosis and Vascular Biology (2002), 22: 141-146.

 

108.          Rubin J, Paultre F, Tuck CH, Holleran S, Reed RG, Pearson TA, Thomas CM, Ramakrishnan R, Berglund L. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. Journal of Lipid Research (2002), 43: 234-244.

 

109.          Humphries SE, Berglund L, Isasi CR, Otvos JD, Kaluski D, Deckelbaum RJ, Shea S, Talmud PJ. Loci for CETP, LPL, LIPC, and APOC3 affect plasma lipoprotein size and subpopulation distribution in Hispanic and non-Hispanic white subjects: The Columbia University BioMarkers Study. Nutrition Metabolism and Cardiovascular Disease (2002), 12: 163-172.

 

110.          Jeng JS, Sacco RL, Kargman DE, Boden-Albala B, Paik MC, Jones J, Berglund L. Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: The Northern Manhattan Stroke Study. Atherosclerosis (2002), 165: 317-325.

 

111.          Isasi CR, Deckelbaum RJ, Tracy RP, Starc TJ, Berglund L, Shea S. Physical fitness and C-reactive protein level in children and young adults: The Columbia University BioMarkers Study. Pediatrics (2003), 111: 332-338.

 

112.          Shea S, Aymong A, Zybert P, Berglund L, Shamoon H, Deckelbaum RJ, Basch CE. Fasting Plasma insulin modulates Lipid Levels and particle sizes in 2- to 3-year old children. Obesity Research (2003), 11: 709-721.

 

 

 

113.          Wu HD, Berglund L, Dimayuga C, Jones J, Sciacca RR, DiTullio MR, Homma S. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. Journal of the American College of Cardiology (2004), 43: 1828-1833.

 

114.          Lind S, Rudling M, Ericsson S, Olivecrona H, Eriksson M, Borgstrom B, Eggertsen G, Berglund L, Angelin B. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arteriosclerosis, Thrombosis, and Vascular Biology (2004), 24: 349-356.

 

115.          Shachter NS, Rabinowitz D, Stohl S, Conde-Knape K, Cohn JS, Deckelbaum RJ, Berglund L, Shea S. The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis (2005), 179: 387-397.

 

116.          Thomas-Geevarghese A, Raghavan S, Minolfo R, Holleran S, Ramakrishnan R, Ormsby B, Karmally W, Ginsberg HN, El-Sadr WM, Albu J, Berglund L. Postprandial response to a physiological caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy¹ֿ³. American Journal of Clinical Nutrition (2005), 82: 146-54.

 

117.          Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN, Treatment with high-dose simvastatin reduces secretion of apolipoprotein B – lipoproteins in patients with diabetic dyslipidemia. Journal of Lipid Research (2005), 46: 2735-2744.

 

118.          Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, Sydow K, Lau D, Szöcs K, Klinke A, Kubala L, Berglund L, Schrepfer S, Deuse T, Haddad M, Risius T, Klemm H, Reichenspurner HC, Meinertz T, Heitzer T. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation (2006), 113: 1871-1878.

 

119.          Rubin J, Kim HJ, Pearson TA, Holleran S, Ramakrishnan R, Berglund L. The Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. Journal of Lipid Research (2006), 47: 982-989.

 

120.          Anuurad E, Rubin J, Lu G, Pearson TA, Holleran S, Ramakrishnan R, Berglund L. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. Journal of Lipid Research (2006), 47: 2475-2481.

 

121.          Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA, Ormsby B, Berglund L. Adiponectin levels are assocated with coronary artery disease across Caucasian and African American ethnicity. Translational Research (2007), 149: 317-323.

 

122.          Anuurad E, Lu G, Rubin J, Pearson TA, Berglund L. ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: The Harlem-Basset study. Journal of Lipid Research (2007), 48: 693-698.

 

123.          Anuurad E, Chiem A, Pearson TA, Berglund L. Metabolic syndrome components in African Americans and European-Americans patients and its relation to coronary artery disease. American Journal of  Cardiology (2007), 100: 830-834.

 

124.          Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim PS, Ramakrishnan R, Reed R, Stewart K, Phillips KM for the DELTA Investigators. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: Studies in the fasting and postprandial state¹ֿ³. American Journal of Clinical Nutrition, (2007), 86: 1611-1620.

 

125.          Anuurad E, Thomas-Geevarghese A, Devaraj S, Albu J, Minolfo R, El-Sadr W, Lu G, Karmally W, Berglund L. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis (2007), in press.

 

126.          Rubin J, Kim HJ, Pearson TA, Holleran S, Berglund L, Ramkrishnan R, The apolipoprotein (a) gene: Linkage disequilibris at three loci differs in African Americans and Caucasians. Atherosclerosis (2008), in press

 

127.          Anuurad E, Rubin J, Chiem AT, Tracy RP, Pearson TA, Berglund L. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African Americans. Journal of Clinical Endocrinology and Metabolism (2008), in press.

 

B.   Reviews, chapters and editorials.

 

1.      Engström L, Berglund L, Bergström G, Hjelmquist G, Ljungström O.  Regulatory phosphorylation of purified pig liver pyruvate kinase.  In Lipmann Symposium:  Energy, Biosynthesis and Regulation in Molecular Biology.  (Ed. Richter, E.) Walter de Gryter Ltd, Berlin-New York (1974), pp.192-204.

 

2.      Berglund L. Studies on Pyruvate kinases. (Academic dissertation) Acta Universitatis Upsaliensis (1977), 279.

 

3.      Berglund L, Björkhem I, Angelin B, Einarsson K. Regulation of triglyceride biosynthesis: Studies on hepatic phosphatidic acid phosphatase. In Treatment of hyperlipoproteinemia (Eds: LA Carlsson and AG Olsson), Raven Press, NY (1984), pp 99-102.

 

4.      Björkhem I, Angelin B, Berglund L, Einarsson K, Ewerth S, Lewenhaupt A. Effect of flux of lymph and bile acids on the activity of phosphatidic acid phosphatase in rat liver. In Coordinate regulation of cholesterol metabolism  (Ed: A Sanghvi), Nato Advanced Research Workshop (1985), pp 262-279.

 

5.      Angelin, B, Berglund L, Einarsson K, Ericsson S, Eriksson M.  Disturbances of bile acid metabolism and abnormalities of lipoprotein turnover.  Bile acids and the liver (Eds: G Paumgartner, A Stiehl and W Gerok)  MTP Press Ltd, Lancaster (1987), pp 277-280.

 

6.      Lantz, B, Berg B, Berglund L, Eriksson M, Angelin B. Plasmapheresis in FHC heterozygotes and healthy controls.  In Proceedings of the First International Congress of the World Apheresis Association (Eds: T Oda, Y Shiokawa and N Inoue) ISAO Press no 308, Cleveland (1987), pp 573-575.

 

7.      Henriksson, P, Eriksson M, Stamberger M, Berglund L, Diczfalusy U, Angelin B. Estrogens and atherosclerosis: Studies in the cholesterol-fed rabbit. In Atherosclerosis and Cardiovascular Diseases (Eds: S Lenzzi and GC Descovitch) Editrice Composition, Bologna, Italy (1987), 3:1047-1050.

 

8.      Berglund L, Björkhem I. Leverfunktionsprover.  In Hepatologi I (Eds: F Barany, K Einarsson and LS Eriksson) TIKA Förlag, Lund, Sweden (1988), pp 149-161.

 

9.      Angelin, B, Ericsson S, Eriksson M, Berglund L, Einarsson K.  Bile acids and low-density lipoprotein metabolism: Studies in familial hypertriglyceridemia, old age, and during chenodeoxycholic acid therapy. In Trends in Bile Acid Research (Eds: G Paumgartner, A Stiehl and W Gerok.) Kluwer Academic Publishers, Dorderecht/Boston/London (1989), pp 217-218.

 

10.  Emtestam, L, Berglund L, Angelin B, Kappas A.  Treatment of psoriasis vulgaris with a synthetic metalloporphyrin and UVA light. Acta Dermatologica Venereologica (1989), Suppl 146: 107-110.

 

11.  Björkhem I, Berglund L. Nya farmaka vid ateroskleros i sikte. Antioxidantia hämmar LDL-modifiering. (Development of new anti-atherogenic drugs. Antioxidants prevents modification of LDL). Läkartidningen (Bulletin of the Swedish Medical Association) (1989), 86: 3249-3255.

 

12.  Angelin B, Ericsson S, Eriksson M, Berglund L. Effects of nicotinic acid on lipoprotein metabolism and biliary lipids. In Atherosclerosis VIII (Eds. G Crepaldi et al) Elseviers Science Publishers B.V. (1989), pp 795-798.

 

13.  Ericsson S, Angelin B, Berglund L, Einarsson K.  Influence of age on plasma low density lipoprotein metabolism in man.  In Liver and Aging. (Ed: K Kitani) Elsevier Science Publishers B.V. (1991), pp 295-304.

 

14.  Berglund L, Eggertsen G, Hagve T-A. Analys av genetisk variation av apolipoprotein E - kliniskt betydelsefullt vid riskvärdering av hjärt-kärlsjukdom? (Genetic variation of apolipoprotein E - of clinical importance in the evaluation of cardiovascular disease?). Klinisk kemi i Norden (Clinical Chemistry in Scandinavia) (1993), 5: 27-30.

15.  Berglund L, Angelin B, Eggertsen G, Eriksson M, Henriksson P. Apolipoproteinanalyser i klinisk diagnostik (On the use of analysis of apolipoproteins in clinical diagnostics).  Läkartidningen (Bulletin of the Swedish Medical Association) (1994), 91: 716-724.

 

16.  Berglund L.  Diet and drug therapy for lipoprotein (a).  Current Opinion in Lipidology (1995) 6: 48-56.

 

17.  Stenvinkel P, Berglund L.  Lipoprotein (a) in chronic renal disease.  Mineral Electrolyte Metabolism (1996), 22: 16-21.

 

18.  Gorelick PB, Schneck M, Berglund L, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology (1997), 16: 107-115.

 

19.  Heimburger O, Stenvinkel P, Berglund L. Plasma lipoprotein (a) is related to peritoneal albumin losses. Nephron (1997), 76: 241.

 

20.  Berglund L. A recurrent theme with a new spin: ACE polymorphism and cardiovascular disease. Journal of Laboratory and Clinical Medicine (1998), 131: 485-486.

 

21.  Werynski A, Nahorski Z, Angelin B, Berglund L, Eriksson M. Kinetic analysis of LDL apoB transport and metabolism in non-steady states. Control and Cybernetics (2000), 29: 405-425.

 

22.  Berglund L. The APOE gene and diets – food (and drink) for thought¹ˉ². American Journal of Clinical Nutrition (2001), 73: 669-670.

 

23.  Thomas AM, Berglund L. Editorial: Growth hormone and cardiovascular disease: An area in rapid growth. Journal of Clinical Endocrinology and Metabolism (2001), 86: 1871-1873.

 

24.  Rubin J, Berglund L. The Apolipoprotein E and diets: A case for gene-nutrient interaction? Current Opinion in Lipidology (2002), 13: 25-32.

 

25.  Berglund L. Lipoprotein A: Where does the atherogenicity reside? Journal of Laboratory and Clinical Medicine (2002), 139: 131-132.

 

26.  Berglund L. Postprandial lipemia and obesity -  any unique features?¹´² American Journal of Clinical Nutrition (2002), 76: 299-300.

 

27.  Jialal I, Berglund L. Therapy and clinical trials. Current Opinion in Lipidology (2003), 14: 227-231.

 

28.  Berglund L. Lipid Biochemistry: An Introduction. 5th Edition. (Eds: M.I. Gurr, J.L. Harwood, K.N. Frayn) Blackwell Science Ltd, Oxford, UK. American Journal of Clinical Nutrition (2003), 78: 353-354.

29.  Berglund L, Hyson D. Cholesterol absorption and the metabolic syndrome. A new look at an old area. Arteriosclerosis, Thrombosis and Vascular Biology (2003), 23: 1314-1316.

 

30.  Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease.  Current Atherosclerosis Report (2003), 5: 437-444.

 

31.  Berglund L. Book review. Nutrition and Heart Disease: Causation and Prevention, 1st Edition. (Eds: RR. Watson, V.R. Preddy) CRC Press, Boca Raton, FL. The American Journal of Clinical Nutrition (2004), 80: 1670-1672.

 

32.  Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor.  Arteriosclerosis, Thrombosis and Vascular Biology (2004), 24: 2219-2226.

 

33.  Lu G, Berglund L. ApoE- A strong candidate for gene-nutrient interaction?  Sociedad Iberoamericana de Información Científica (SIIC), (2005).

 

34.  Berglund L. Cardiovascular Disease: Diet, Nutrition and Emerging Risk Factors. (Ed: S Stanner) Blackwell Publishing, Oxford, UK. American Journal of Clinical Nutrition (2005), 82: 1359.

 

35.  Berglund L. Adipose tissue, skeletal muscle, and insulin resistance across ethnicities – systems biology in action¹´². American Journal of Clinical Nutrition (2005), 85: 1153-1154.

 

36.  Discepolo T, Wun T, Berglund L. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiology of Haemostasis and Thrombosis (2006), 35: 314-321.

 

37.  Berglund L. Lipoprotein metabolism: A well-tried tool to characterize dyslipidemic mechanisms. Arteriosclerosis, Thrombosis and Vascular Biology (2006), 26: 1201-1203.

 

38.  Erdembileg A, Boffa M, Koschinsky M, Berglund L. Lipoprotein(a): A unique risk factor for cardiovascular disease. Clinics in Laboratory Medicine (2006), 26: 751-772.

 

39.  Berglund L. Book review. Textbook on Nutrition and Aids, 3rd Edition. (Ed: R. Polo) NILO Industria Grafica, Madrid Spain. The American Journal of of Clinical Nutrition (2006), 84: 1556-1557.

 

40.  Zou W, Berglund L. HIV and highly active antiretroviral therapy (HAART): Dyslipidemia, metabolic aberrations and cardiovascular risk. Preventive Cardiology (2007), 10: 96-103.

 

41.  Anuurad E, Berglund L. Apolipoprotein E and cardiovascular disease. Indian Journal of Medical Sciences (2008), in press.

 

 

 

 

 

C. Selected abstracts 1999-2007.

 

1.      Anuurad E, Tracy RP, Pearson TA, Berglund L. The combination of insulin resistance and inflammationis a cardiovascular risk factor in both African Americans and Caucasians: The Harlem-Bassett Study. Submitted to the annual meeting of the Endocrine Society, 2008

 

2.      Anuurad E, Chiem A, Tracy RP, Pearson TA, Berglund L. Inflammation results in increased allele-specific apo(a) levels in African Americans: Potential explanation for inter-ethnic difference? Circulation 2007: 115: in press.

 

3.      Anuurad E, Thomas-Geevarghese A, Minolfo R, Karmally W, Zou W, Devaraj S, El-Sadr W, Albu J, Berglund L. Antiretroviral therapy in HIV-positive patients results in a pro-atherogenic postprandial pattern with increased lipoprotein remnant cholesterol levels. Circulation 2006; 114: II-114-5.

 

4.      Anuurad E, Lu G, Berglund L. Genetic determinants of lipoprotein(a): ApoE genotype predicts allele-specific apo(a) levels in African Americans.  Circulation 2006; 114: II-255-6.

 

5.      Chiem A, Tsodikov A,  Berglund L. The Role of the Metabolic Syndrome as a Risk Factor for Coronary Artery Disease across gender and ethnicity. Poster presentation at the 7th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2006.

 

6.      Zou W, Lu G, Thomas-Geevarghese A, Ormsby B, Berglund L. The Kinetics of Plasma Leucine, alpha-Ketoisocaproate, VLDL Apolipoprotein B-100: Effects of HIV. Poster presentation at the 7th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2006.

 

7.      A Thomas-Geevarghese, G Lu, S Raghavan, R. Minolfo, S Holleran, R Ramakrishnan, B Ormsby, W Karmally, W El-Sadr, L Berglund, J Albu Choice of protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based Highly Active Antiretroviral Therapy (HAART) in HIV-positive subjects affects postprandial adiponectin, free fatty acid, leptin and insulin response. The Endocrine Society’s 87th Annual Meeting 2005.

 

8.      N Rassouli, JA Johnson, G Ionescu, R Minolfo, ES Engelson, W El-Sadr, DP Kotler, L Berglund, J Albu, Antiretroviral Therapy (ART) but not HIV Infection is associated with Abnormal Fat Distribution and Increased Subcutaneous Adipose Tissue (SAT) Secretion of IL6 and TNF-Alpha. The Endocrine Society’s 87th Annual Meeting 2005.

 

9.  Berglund L, Pathogenesis of Dyslipidemia in HIV. Oral presentation at the 12th Conference on Retrovirus and Opportunistic Infections, Abstract 60, 2005.

 

10.  Lu G, Kubala L, Berglund L, Eiserich JP. Plasma myeloperoidase levels do not predict risk in patients with stable coronary artery disease. Arteriosclerosis, Thrombosis and Vascular Biology 2005; 22: A1. (Poster presentation at the 6th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2005).

 

11.  Lu G, Powers A, Ormsby B, Rutledge JC, Berglund L. Lipoprotein (a) with small size apo(a) has higher arterial wall accumulation rate than LDL and localizes to the endothelial cell layer. Arteriosclerosis, Thrombosis and Vascular Biology 2005; 22: A1. (Poster presentation at the 6th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2005).

 

12.  Berglund L, Rubin J, Pearson TA, Holleran S, Ramakrishnan R. The apo(a) size, C/T, and PNR polymorphisms in Lp(a): A population genetic study of linkage in African Americans and Caucasians. Arteriosclerosis, Thrombosis and Vascular Biology 2004; 22: A1. (Poster presentation at the 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2004).

 

13.   Lu G, Pearson TA, Havel PJ, Ormsby B, Holleran S, Ramakrishnan R., Berglund L. Adiponectin is a risk factor for coronary artery disease in diabetes mellitus: Studies in whites and blacks. Arteriosclerosis, Thrombosis and Vascular Biology 2004; 22: A1. (Oral presentation at the 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2004).

 

14.  Berglund L, Reed RG, Rubin J, Holleran S, Ramakrishnan R, Pearson, TA. Protective effect of apolipoprotein E2 on angiographically determined heart disease in African Americans is mediated through serum lipoprotein cholesterol. Arteriosclerosis, Thrombosis and Vascular Biology 2002; 22: A1. (Poster presentation at the 3rd Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2002).

 

15.  Thomas-Geevarghese A, Raghavan S, Marshall K, Holleran S, Ramakrishnan R, Karmally W, El-Sadr W, Albu J, Berglund L. Hyperinsulinemia in non-Caucasian HAART-treated HIV-positive patients. The Endocrine Society’s 84th Annual Meeting 2002, p. 413.

 

16.  Shea S, Aymong E, Zybert P, Berglund L, Shamoon H, Tracy R, Deckelbaum R, Basch C. Obesity is related to level of fasting insulin but not C-reactive protein (CRP) in healthy 2- to 3-year old children. Circulation 2002; 106: II-726 (Presentation, 75th Scientific Sessions of the American Heart Association, 2002).

 

17.  Shea S, Aymong E, Zybert P, Berglund L, Shamoon H, Tracy R, Deckelbaum R, Basch C. Fasting plasma insulin level is related to increased levels of triglycerides and C-reactive protein in healthy 2- to 3-year old children. Circulation 2002; 106: II-766 (Presentation, 75th Scientific Sessions of the American Heart Association, 2002).

 

18.  Paultre F, Jones J, Fontanez N, Todd E, Tuck CH, Kahn S, Ramakrishnan R, Berglund L. LDL is not the major precursor for Lipoprotein(a): Stable isotope studies in Caucasians and African Americans. Circulation 2001; 104: II-311 (Oral presentation, 74th Scientific Sessions of the American Heart Association, 2001).

 

19.  Raghavan S, Albu J, Marshall K, Thomas A, Jones J, Schliep T, Littschwager M, Holleran S, Karmally W, El-Sadr W, Berglund L. Postprandial lipemia during a physiological caloric load in non-caucasian highly active antiretroviral therapy-treated HIV-positive patients. Antiviral Therapy 2001; 6 (Suppl 4): 69.

 

20.  Rubin J, Kim HJ, Ramakrishnan R, Berglund L. Differential distribution of the apolipoprotein(a) gene +93 C/T and pentanucleotide repeat (PNR) polymorphisms across apo(a) gene size and ethnicity. Arteriosclerosis, Thrombosis and Vascular Biology 2001; 21: 680. (Oral presentation at the 2nd Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2001).

 

21.  Rubin J, Paultre F, Tuck CH, Reed RG, Pearson TA, Ramakrishnan R, Berglund L. Isoform-specific levels of Lp(a) are not solely determined by apo(a) allele size: Studies in Caucasians and African Americans. Arteriosclerosis, Thrombosis and Vascular Biology 2001; 21: 659. (Poster presentation at the 2nd Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association 2001).

 

22.  Berglund L, Holleran S, Ramakrishnan R, Ginsberg HN for the DELTA Investigators. Leptin levels are not affected by changes in dietary fat during weight maintenance. Circulation 2000; 102: II-379. (Oral presentation, 73rd Scientific Sessions of the American Heart Association, 2000).

 

23.  Worgall TS, McGovern MM, Jiang XJ, Berglund L, Isasi C, Shea S, Tabas IA, Deckelbaum RJ. Mutations in the acid sphingomyelinase gene are associated with very atherogenic lipoprotein profiles in humans. Circulation 2000; 102: II-30. (Oral presentation, 73rd Scientific Sessions of the American Heart Association, 2000).

 

24.  Fard A, Pinney SP, Vest JA, DiTullio MR, Berglund L, Ginsberg HN, Rabbani LE, Schwartz A, Cannon P, Homma S. Independent association of asymmetric dimethylarginine (ADMA) with presence and severity of coronary artery disease. Circulation 2000; 102: II-757  (Oral presentation, 73rd Scientific Sessions of the American Heart Association, 2000).

 

25.  Berglund L. Lipoprotein(a) as a risk factor for cardiovascular disease. Atherosclerosis 2000; 151: 231

 

26.  Rubin J, Paultre F, Reed R, Pearson TA, Ramakrishnan R, Berglund L. Complexity of association between apo(a) gene size & Lp(a) levels in Caucasians & African Americans – does size matter? Atherosclerosis 2000; 151: 246

 

27.  Tsai M, Schermer C, Lu Y, Ferran L, Moss R, Casey J, Do E, Stern DM, Berglund L, Huang LS, Schmidt AM. Modulation of lipid profile and atherosclerosis in genetically diabetic transgenic mice expressing apolipoprotein B. Circulation 1999; 100: I-696 (Poster presentation, 72nd Scientific session, American Heart Association, 1999)

 

28.  Fard A, Donis JA, Tuck C, DiTullio MR, Wu H, Huang ML, Chen NT, Torres-Tamayo M, Ginsberg HN, Berglund L, Homma S, Cannon P, lasma asymmetric dimethylarginine is elevated and endothelial function is impaired after a high-fat meal in type 2 diabetics. Circulation 1999; 100: I-701. (Poster presentation, 72nd Scientific session, American Heart Association, 1999)

 

29.  Berglund L, Isasi CR, Starc TJ, Shamoon H, Ginsberg HN, Deckelbaum RJ, Shea S. Relative fasting hyperinsulinemia is associated with low HDL cholesterol and high triglyceride levels in normal, healthy children: The Columbia BioMarkers Study. Circulation 1999; 100: I-197. (Oral presentation, 72nd Scientific session, American Heart Association, 1999)

 

30.  Kargman DE, Berglund L, Boden-Albala B, Lin IF, Paik M, Sacco RL. Increased stroke risk and lipoprotein(a) in a racially mixed area: The Northern Manhattan Stroke Study. Presentation at the 24th International Conference on Stroke and Cerebral Circulation, American Heart Association, 1999.

 

31.  Jeng JS, Sacco RL, Liu RC, Kargman DE, Boden-Albala B, Jones J, Berglund L. Association of apolipoproteins to carotid artery atherosclerosis: The Northern Manhattan Stroke Study. Presentation at the 24th International Conference on Stroke and Cerebral Circulation, American Heart Association, 1999.

 

32.  Fard A, Donis JA, DiTullio MR, Wu H, Mendoza LM, Titova IV, Ramakrishnan R, Torres-Tamayo M, Tuck C, Berglund L, Ginsberg H, Homma S. The effects of a high-fat meal on endothelial function in patients with type 2 diabetes. Abstract presented at the 48th Annual Scientific Session of the American College of Cardiology, 1999.

 

33.   Isasi CR, Couch SC, Starc T, Berglund L, Deckelbaum RJ, Shea S. Is there an association of fitness level with fibrinogen level in cildren independent of obesity? The Columbia BioMarkers Study. Poster presentation, 39th Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association, 1999.